Background: Ventilator-Associated Pneumonia (VAP) is one of the frequent intensive-care-unit (ICU)-acquired infection. The aetiology of VAP varies with patients' profiles and ICU settings. Due to the increasing incidence of multidrug-resistant organisms in ICUs, early and correct diagnosis of VAP is an urgent challenge for an optimal antibiotic treatment. The aim of the study was to assess the incidence of VAP in different patients by various organisms to create a database of the causative agents of VAP, their drug resistance profile in that area. Methodology: A prospective study was done over a period of 12 months in a rural tertiary care hospital enrolling patients undergoing mechanical ventilation (MV) for >48 h. Samples were collected from patients with suspected VAP, cultures were performed on all samples. VAP was diagnosed by the growth of significant pathogens. Combination disk method, EDTA disk synergy (EDS) test and cefoxitin double disc synergy test were performed for the detection of different patterns of drug resistance. Results: Culture positive cases were 52.29% of total. Acinetobacter spp, Klebsiella pneumoniae and Staphylococcus aureus were most frequent pathogen in early-onset VAP, while Pseudomonas spp. and Acinetobacter spp. dominated the list of pathogens responsible for lateonset VAP. Prior antibiotic therapy and hospitalization of five days or more were independent risk factors for VAP by MDR pathogens. Conclusions: This study highlighted high incidence of VAP in our setup. Production of ESBL, AmpC beta-lactamases and metallo beta-lactamases were responsible for the multi-drug resistance of the pathogens causing VAP, implicating the injudicious use of antimicrobial therapy. Combined approaches of rotational antibiotic therapy and education programs might be beneficial to fight against these MDR pathogens to decrease the incidence of VAP.
Introduction
Patients admitted in the intensive care unit (ICU) are at risk for dying not only from their illness but from added insults such as nosocomial infections (NI) also. Pneumonia is the second commonest NI in critically ill patients, after UTI, affecting 27% of all critically ill patients 1 . Ventilator-associated pneumonia (VAP) is defined as pneumonia occurring more than 48 hours after endotracheal intubation and initiation of mechanical ventilation (MV) including pneumonia developing even after extubation 2 . VAP is the most frequent intensive-care-unit (ICU) acquired infection, occurring in 9 to 24% of patients intubated for longer than 48 hours 3, 4 . Earlyonset VAP, occurring during the first four days of mechanical ventilation (MV), usually is less severe, associated with a better prognosis, and is more likely to be caused by lesser resistant strains of bacteria. Late-onset VAP, develops five or more days after initiation of MV, is caused by multidrug-resistant (MDR) pathogens and is associated with higher degree of morbidity and mortality 5 . Diagnosing VAP requires a high clinical suspicion combined with bedside examination, radiographic examination, and microbiologic analysis of respiratory secretions. Reasonable clinical criteria for the suspicion of VAP include a new and persistent (>48h) or progressive radiographic infiltrate plus two of the following: temperature of >38°C or <36°C, blood leukocyte count of >10,000 cells/ml or <5,000 cells/ml, purulent tracheal secretions, and gas exchange degradation 1 . Aggressive surveillance is vital in understanding local factors leading to VAP and the microbiologic milieu of a given unit. VAP may be caused by a wide spectrum of bacterial pathogens, which may be polymicrobial and are rarely due to viral or fungal pathogens in immunocompetent hosts 2, 7 Common pathogens include aerobic gram-negative bacilli, such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Acinetobacter species. Infections due to gram-positive cocci, such as Staphylococcus aureus, are more common in patients with diabetes mellitus and head trauma 7 . The frequency of specific MDR pathogens causing VAP may vary by hospital, patient population, exposure to antibiotics, type of ICU patient and changes over time, emphasizing the need for timely local surveillance data 7 . Detection of the causative organism is crucial for the diagnosis of VAP. This is done by collecting the lower respiratory tract sample either by invasive (protected specimen brush [PSB] or broncho-alveolar lavage [BAL]) or noninvasive (endotracheal aspirate [ETA]) techniques and culturing quantitatively or semi-quantitatively. The major difficulty of this approach is in obtaining samples from the lower respiratory tract -mainly because of its probable contamination with the upper airway flora, which may result in misinterpretation of cultures 8 . The American Thoracic Society (ATS) guidelines recommend that quantitative cultures can be performed on ETA or samples collected either bronchoscopically or nonbronchoscopically 9 . Reliance on semi-quantitative cultures, which may not reliably separate true pathogens from colonizers, can lead to either more or broader-spectrum antibiotic therapy than with a quantitative approach. On the other hand, there are many studies which compared the diagnostic value of quantitative cultures of bronchoscopic and nonbronchoscopic samples in VAP. No technique could consistently be shown to achieve a superior diagnostic yield as compared with another. Another advantage in terms of costlower respiratory tract sample collection through endotracheal tube is much less expensive compared to BAL or PSB and hence is widely preferable in most of the hospital settings. Judicious antibiotic usage is essential, as resistant organisms continue to plague intensive care units and critically ill patients. Pseudomonas spp., Acinetobacter spp. and even Enterobacteriaceae are quite often multidrugresistant due to production of extended spectrum beta (β)-lactamases (ESBL), AmpC β-lactamases (AmpC) or metallo-β-lactamases (MBL) 9 . The aetiological agents of VAP vary with different patient populations and types of ICUs 2 . Therefore, the local microbial flora causing VAP needs to be studied in each setting to guide more effective and rational utilization of antimicrobial agents. The objectives of this study were to determine the prevalence and risk factors of MDR pathogens among our VAP patients and to determine their antibiotic susceptibility pattern as well as detect the presence of ESBL, AmpC β-lactamases, carbapenemases and metallobetalactamases in these VAP pathogens.
Material and Methods
This study was a prospective observational one conducted in the intensive care units (ICU) and in the Dept. of Microbiology of Burdwan Medical College & Hospital which is a medical College in Burdwan District, West Bengal, from Jan 2012 to December 2012. This study was approved by the institutional Ethical committee. The ICU is comprised of 12 well-spaced beds and patients were either admitted directly to the ICU or transferred from other departments. During 12 months study period a total 113 patients who were intubated and received mechanical ventilation in the ICU were reviewed prospectively. Among them four patients were found to develop pneumonia within 48 hours of initiation of MV and hence excluded from study. So, remaining 109 patients were included in the study. . The samples were then plated on sheep blood agar (SBA), chocolate agar (CA), MacConkey agar (MA) by using 4 mm Nichrome wire loop (Hi-media, Mumbai, India), which holds 0.01 ml of solution. All plates were then incubated overnight at 37°C at 37°C in 5% CO 2 incubator. All plates were checked for growth overnight and then after 24 and 48 h of incubation. For definite diagnosis of VAP in this study, quantitative culture threshold was considered as 10 5 cfu/ml. Growth of any number of organism below this level was considered to be due to colonization or contamination and therefore not processed further 7 . Bacterial isolates were identified using conventional biochemical battery of tests namely sugar fermentation test, indole production, MR-VP,Citrate utilization, Urease production, TSItest,PPA, amino acid decarboxylation tests , Oxidase tests etc. Following this anitimicrobial susceptibility testing (AST) was performed by Kirby-Bauer disc-diffusion technique. Selection of battery of antimicrobials was done following the guideline of CLSI document 2011 11 for Enterobacteriaceae, Pseudomonas spp, Acinetobacter, Staphylococcus aureus. Detection of methicillin resistance in Staphylococcus aureus has been done by using cefoxitin (30mcg) disc in Muller Hinton agar plate (MHA). ESBL production by enterobacteria has been confirmed by combination disc test using Cefotaxime alone & Cefotaxime-clavulenic acid and Ceftazidimealone & Ceftazidime-clavulenic acid discs. Any increase in 'zone of inhibition' diameter by ≥5mm around the disc containing Clavulenic acid in comparison to the original disc (Cefotaxime/ Ceftazidime) is indicative of ESBL production by the test isolate. AmpC detection was performed by both screening test by Cefoxitin (30mcg) disc followed by phenotypic confirmatory test i.e. cefoxitincloxacillin double disc synergy test (CC-DDS). This test is based on the inhibitory effect of cloxacillin on AmpC. Disks containing either 30 μg of cefoxitin and 30 μg of cefoxitin plus 200 μg of cloxacillin were procured for the present study. The screen positive isolates were inoculated on Mueller-Hinton agar using McFarland 0.5, followed and incubated at 35°C for 16 to 18 h. A difference in the cefoxitincloxacillin inhibition zones minus the cefoxitin alone zones of ≥4 mm was considered indicative for AmpC production. Amp C detection for Citrobacter fruendii is not done because of the the fact that it produces chromosomally encoded Amp C 12 . Detection of metallo-β-lactamases (MBL) has been done by EDTA disk synergy test (EDS) using both meropenem and ceftazidime discs. Appearance of an expanded zone of inhibition between meropenem or ceftazidime and EDTA discs was interpreted as positive for MBL production.
Results:
A total 203 patients were admitted in the ICU of the institution in the above mentioned study period (one year) and 109 patients were enrolled for the study according to the inclusion criteria. Quantitative culture results were significant (≥10 5 cfu/ml) for pathogenic organisms causing VAP in 57 (52.29%) patients. Fifty-two (47.71%) patients did not have VAP, and they served as non-VAP control group. Patients developing VAP within 96 h of MV were categorized as having 'early-onset VAP,' and those having it after 96 h were classified as 'late-onset VAP.' Out of these 57 cases, 21(36.84% ) were categorized under the early-onset group and the remaining 36 (63.16% ) under the late-onset group. The incidence of VAP increased with the duration of MV. The median duration of MV in non-VAP group was 3.6 days as against 15.5 days in patients with VAP (P<0.05) [Mann-Whitney test]. The clinical spectrum of the patients as evident from Table 1 shows that highest number of VAP cases occur in the setting of post operative MV (12/57) followed by CRF/ARF/DM/HTN/IHD cases (11/57), road traffic accident, malignancy ,organophosphate poisioning, CVA, acute pancreatitis, FUO, cirrhosis of liver and malaria. Acinetobacter spp. was the commonest organism (n=20) to be isolated from clinical samples in the VAP cases (culture positive cases) followed by Pseudomonas aeruginosa (14) , Klebsiella pneumonia ( 10) , Staphylococcus aureus (6) Amp-C betalactamase production has been observed with diverse frequency. All the isolates of Enterobacter spp. are Amp-C producer here. Whereas, 60% of the Klebsiella pneumonia and 33.3% of the Proteus mirabilis isolates in this study are Amp-C betalactamase producers (Table 3) . 
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50 ( 10) 71.5 (10) 70 (7) 100 (3) 66.6 (4) 50 (1) 00 Cefepime (%) 40 (8 ) 64.28 (9) 40 (4) (2) 50 (1) 50 (1) Va n c o m y c i n (%) isolates in this study when tested against Polymyxin B were sensitive except one Klebsiella pneumonia isolate. Tigecycline was ineffective against five (out of ten), one (out of three) and one (out of two) isolates of Klebsiella pneumonia, Citrobacter fruendii and Enterobacter spp respectively. All of three Proteus isolates are sensitive to Tigecycline. Pip-tazo was also ineffective against most of the organism in this study.
Out of six Staphylococcus aureus isolates five were Meticillin resistant. These isolates are fully susceptible to Vancomycin, Teicoplanin and fairly so to linezolid (1 isolate resistant) and tigecycline (2 isolates resistant) .However, Staphylococcus aureus in the present study is highly resistant to ciprofloxacin (83.3%) and levofloxacin (66.6%) but not so towards gentamicin (33.3%).
Discussion
The incidence of culture positive VAP in our setting was 52.29 %. In the era of advanced diagnosis and early management of possible complications, the incidence should have to be lower. As found in some recent studies the incidences are reported to be low 7, 13 . The high incidence in our study may be due to a higher number of cases (i.e., 57) and lack of adequate nursing staff which may have adversely affected the quality of care given to the patients. Another factor in our study was a high number of post operative cases and chronic debilitating illness cases admitted in ICU that required prolonged ventilation, which was proved to be risk factor for VAP. But in contrast to some other studies where organophosphate poisoning was the commonest background cause 13 , here highest number of VAP cases were emerged from the background of post-operative illness (12 out of 57) and chronic debilitating illness e.g.-CRF/ ARF/DM/HTN/IHD(11 out of 57). This finding is in accordance with the study of Peter George et al. who found chronic debilitating illness viz. Diabetes mellitus, hypertension as the most frequent causes for development of VAP in their study 14 . Other conditions requiring prolonged MV have also found to be serious causes for precipitation of VAP. Multidrug resistant organisms are increasing in our ICUs. Earlier studies have shown that Pseudomonas is the most common organism 15 . In the present study multidrug resistant Acinetobacter spp. became the commonest pathogen followed by P. aeruginosa, and K.pneumoniae to cause VAP. This emphasizes the need to treat the cases of VAP with second-line antibiotics effective against these MDR pathogens. The findings also warrant the needs for stringent preventive measures for VAP, as the treatment of an established VAP becomes very expensive. Non-fermenters such as Pseudomonas spp. and Acinetobacter spp. were significantly associated with late-onset VAP as it was seen by other workers 16, 17 . But in the present study patients with early-onset VAP had Acinetobacter spp. as the commonest pathogen. Besides Acinetobacter spp. the other common pathogens for early -onset VAP were K.pneumoniae and S.aureus (all 5 isolates were MRSA), here. This is in contrast to what obtained by Parija et al. as they found MRSA mostly in late-onset VAP cases 18 . Late-onset VAP was associated with higher rates of infection with polymyxin-B resistant MDR Acinetobacter spp., but the resistance of the non-fermenters to the other antibiotics was almost the same in both early-and late-onset VAP as found in the study. In fact all the polymyxin-B resistant isolates of Acinetobacter spp have been confronted in late-onset VAP cases. Most of the early-onset VAP cases had the history such as prior antibiotic therapy and current hospitalization for five days or more. That could be the reason for the almost similar AST patterns of the isolates from lateonset and early-onset VAP. The American Thoracic Society guidelines support the same reasoning by saying that patients with early-onset VAP who have received prior antibiotics or who have had prior hospitalization within the past 90 days are at greater risk for colonization and infection with drug resistant pathogens and should be treated similarly to patients with late-onset VAP 5 . 100% of the K.pneumoniae, C.fruendii, Enterobacter spp. isolates were ESBL producers in this study. One out of the three isolates of Proteus mirabilis was non-ESBL. In a similar type of study by Parija et al,at JIPMER, Pondicherry, they found ESBL produced by 50% and 67% of E. coli and K. pneumoniae respectively, in their study. The high degree of drug resistance in our study may be indicative of poor infection control measures and a need of thorough revision of the institutional antimicrobial policy. Likewise, metallo-betalactamases (MBL) production have been observed in all of the gramnegative pathogen encountered in the study except Enterobacter spp. Klebsiella spp. was associated with maximum production of MBL(83.3%) followed by 21 . But low frequency of Amp-C production (33.3% among Enterobacteriaceae) has been observed by Parija et al 18 . From the present study, the need for judicious selection of patients for antibiotic therapy is emphasized. The prophylactic use of antibiotics is not recommended, and exposure to antibiotics is a significant risk factor for colonization and infection with nosocomial multidrug-resistant pathogens as observed by other authors 2, 22 . The rational use of appropriate antibiotics may reduce patient colonization and subsequent development of VAP. Likewise, unnecessary prolonged hospital stay of the patients should be avoided as far as possible. But it may not be feasible in most situations due to patients' condition.
As the study was conducted in a resource-limited setting, only small number of patients with VAP in a single center were studied, which could be considered a limitation of our study. In addition, we recognize that the findings of this study may not necessarily reflect the situations in other similar centers in India. Hence, we suggest further multi-centered studies with larger patient numbers to confirm our findings, in particular the high incidence of MDR pathogens.
Conclusion
In conclusion, VAP is associated with MDR pathogens. Production of ESBL, AmpC β-lactamases and metallo β-lactamases were responsible for the multidrug resistance of these pathogens. Here, knowledge of the incidence of pathogens and susceptibility pattern of them could guide the choice of antibiotics, in addition to the likelihood of organisms (early-or late-onset VAP). Judicious use of antibiotics can reduce the burden of drug resistance to the vulnerable patient population of ICU.
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